aTyr Pharma Inc
Change company Symbol lookup
Select an option...
LIFE aTyr Pharma Inc
ITT ITT Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp
ROIUF Route1 Inc
MPB Mid Penn Bancorp Inc
NWSA News Corp
BAC Bank of America Corp
BA Boeing Co
EGRNF China Evergrande Group
Go

Health Care : Biotechnology | Small Cap Value
Company profile

aTyr Pharma Inc is a United States-based biotechnology company. The Company engaged in the development of medicines based on biology. The Company’s research and development efforts are concentrated on a new discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

Closing Price
$10.31
Day's Change
0.05 (0.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.54
Day's Low
9.31
Volume
(Light)
Volume:
8,669,072

10-day average volume:
27,308,933
8,669,072

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, September 17, 2021
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D

FinancialNewsMedia.com News Commentary - The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that...(PR Newswire)

September 16, 2021
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...(Globe Newswire)

aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of...(Globe Newswire)

September 15, 2021
aTyr Pharma Announces Proposed Public Offering of Common Stock

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has commenced an underwritten public offering of...(Globe Newswire)

September 14, 2021
Thinking about buying stock in aTyr Pharma, Progenity, AzurRx BioPharma, Rekor Systems, or Akerna Corp?

InvestorsObserver issues critical PriceWatch Alerts for LIFE, PROG, AZRX, REKR, and KERN. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

September 13, 2021
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids. (Globe Newswire)

August 10, 2021
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT. (Globe Newswire)

aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University

Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today announced...(Globe Newswire)

August 09, 2021
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company's lead therapeutic candidate...(Globe Newswire)

August 03, 2021
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide a...(Globe Newswire)

July 29, 2021
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent...(Globe Newswire)

July 08, 2021
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

Results from proof-of-concept study are expected in September 2021. aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced...(Globe Newswire)

June 23, 2021
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29 at 5:00pm ET/2:00pm PT. aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.